PortalPublikationenATG or post-transplant cyclophosphamide to prevent GVHD in m...

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Standard

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? / Penack, Olaf; Abouqateb, Mouad; Peczynski, Christophe; Boreland, William; Kröger, Nicolaus; Stelljes, Matthias; Gedde-Dahl, Tobias; Blau, Igor Wolfgang; Schroeder, Thomas; Salmenniemi, Urpu; Kulagin, Alexander; Peffault de Latour, Régis; Mielke, Stephan; Zeiser, Robert; Moiseev, Ivan; Schoemans, Hélène; Koenecke, Christian; Peric, Zinaida.

in: LEUKEMIA, Jahrgang 38, Nr. 5, 05.2024, S. 1156-1163.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Penack, O, Abouqateb, M, Peczynski, C, Boreland, W, Kröger, N, Stelljes, M, Gedde-Dahl, T, Blau, IW, Schroeder, T, Salmenniemi, U, Kulagin, A, Peffault de Latour, R, Mielke, S, Zeiser, R, Moiseev, I, Schoemans, H, Koenecke, C & Peric, Z 2024, 'ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?', LEUKEMIA, Jg. 38, Nr. 5, S. 1156-1163. https://doi.org/10.1038/s41375-024-02225-7

APA

Penack, O., Abouqateb, M., Peczynski, C., Boreland, W., Kröger, N., Stelljes, M., Gedde-Dahl, T., Blau, I. W., Schroeder, T., Salmenniemi, U., Kulagin, A., Peffault de Latour, R., Mielke, S., Zeiser, R., Moiseev, I., Schoemans, H., Koenecke, C., & Peric, Z. (2024). ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? LEUKEMIA, 38(5), 1156-1163. https://doi.org/10.1038/s41375-024-02225-7

Vancouver

Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? LEUKEMIA. 2024 Mai;38(5):1156-1163. https://doi.org/10.1038/s41375-024-02225-7

Bibtex

@article{78f5e09019da4b948584f301e150eaa1,
title = "ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?",
abstract = "There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in Europe but post-transplantation Cyclophosphamide (PTCy) is an emerging alternative. We analyzed outcomes of rATG (n = 7725) vs. PTCy (n = 1039) prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood alloSCT from 10/10 antigen-matched unrelated donors (MUD) between January 2018 and June 2021 in the EBMT database. The provided P-values and hazard ratios (HR) are derived from multivariate analysis. Two years after alloSCT, NRM in the PTCy group was 12.1% vs. 16.4% in the rATG group; p = 0.016; HR 0.72. Relapse was less frequent after PTCy vs. rATG (22.8% vs. 26.6%; p = 0.046; HR 0.87). Overall survival after PTCy was higher (73.1% vs. 65.9%; p = 0.001, HR 0.82). Progression free survival was better after PTCy vs. rATG (64.9% vs. 57.2%; p < 0.001, HR 0.83). The incidence of chronic GVHD was lower after PTCy (28.4% vs. rATG 31.4%; p = 0.012; HR 0.77), whereas the incidence and severity of acute GVHD were not significantly different. GVHD-free relapse-free survival was significantly higher in the PTCy arm compared to the rATG arm (2 y incidence: 51% vs. 45%; HR: 0.86 [95% CI 0.75-0.99], p = 0.035). In the absence of evidence from randomized controlled trials, our findings support a preference for the use of PTCy in adult recipients of peripheral blood alloSCTs from MUD.",
author = "Olaf Penack and Mouad Abouqateb and Christophe Peczynski and William Boreland and Nicolaus Kr{\"o}ger and Matthias Stelljes and Tobias Gedde-Dahl and Blau, {Igor Wolfgang} and Thomas Schroeder and Urpu Salmenniemi and Alexander Kulagin and {Peffault de Latour}, R{\'e}gis and Stephan Mielke and Robert Zeiser and Ivan Moiseev and H{\'e}l{\`e}ne Schoemans and Christian Koenecke and Zinaida Peric",
note = "{\textcopyright} 2024. The Author(s).",
year = "2024",
month = may,
doi = "10.1038/s41375-024-02225-7",
language = "English",
volume = "38",
pages = "1156--1163",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

AU - Penack, Olaf

AU - Abouqateb, Mouad

AU - Peczynski, Christophe

AU - Boreland, William

AU - Kröger, Nicolaus

AU - Stelljes, Matthias

AU - Gedde-Dahl, Tobias

AU - Blau, Igor Wolfgang

AU - Schroeder, Thomas

AU - Salmenniemi, Urpu

AU - Kulagin, Alexander

AU - Peffault de Latour, Régis

AU - Mielke, Stephan

AU - Zeiser, Robert

AU - Moiseev, Ivan

AU - Schoemans, Hélène

AU - Koenecke, Christian

AU - Peric, Zinaida

N1 - © 2024. The Author(s).

PY - 2024/5

Y1 - 2024/5

N2 - There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in Europe but post-transplantation Cyclophosphamide (PTCy) is an emerging alternative. We analyzed outcomes of rATG (n = 7725) vs. PTCy (n = 1039) prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood alloSCT from 10/10 antigen-matched unrelated donors (MUD) between January 2018 and June 2021 in the EBMT database. The provided P-values and hazard ratios (HR) are derived from multivariate analysis. Two years after alloSCT, NRM in the PTCy group was 12.1% vs. 16.4% in the rATG group; p = 0.016; HR 0.72. Relapse was less frequent after PTCy vs. rATG (22.8% vs. 26.6%; p = 0.046; HR 0.87). Overall survival after PTCy was higher (73.1% vs. 65.9%; p = 0.001, HR 0.82). Progression free survival was better after PTCy vs. rATG (64.9% vs. 57.2%; p < 0.001, HR 0.83). The incidence of chronic GVHD was lower after PTCy (28.4% vs. rATG 31.4%; p = 0.012; HR 0.77), whereas the incidence and severity of acute GVHD were not significantly different. GVHD-free relapse-free survival was significantly higher in the PTCy arm compared to the rATG arm (2 y incidence: 51% vs. 45%; HR: 0.86 [95% CI 0.75-0.99], p = 0.035). In the absence of evidence from randomized controlled trials, our findings support a preference for the use of PTCy in adult recipients of peripheral blood alloSCTs from MUD.

AB - There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in Europe but post-transplantation Cyclophosphamide (PTCy) is an emerging alternative. We analyzed outcomes of rATG (n = 7725) vs. PTCy (n = 1039) prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood alloSCT from 10/10 antigen-matched unrelated donors (MUD) between January 2018 and June 2021 in the EBMT database. The provided P-values and hazard ratios (HR) are derived from multivariate analysis. Two years after alloSCT, NRM in the PTCy group was 12.1% vs. 16.4% in the rATG group; p = 0.016; HR 0.72. Relapse was less frequent after PTCy vs. rATG (22.8% vs. 26.6%; p = 0.046; HR 0.87). Overall survival after PTCy was higher (73.1% vs. 65.9%; p = 0.001, HR 0.82). Progression free survival was better after PTCy vs. rATG (64.9% vs. 57.2%; p < 0.001, HR 0.83). The incidence of chronic GVHD was lower after PTCy (28.4% vs. rATG 31.4%; p = 0.012; HR 0.77), whereas the incidence and severity of acute GVHD were not significantly different. GVHD-free relapse-free survival was significantly higher in the PTCy arm compared to the rATG arm (2 y incidence: 51% vs. 45%; HR: 0.86 [95% CI 0.75-0.99], p = 0.035). In the absence of evidence from randomized controlled trials, our findings support a preference for the use of PTCy in adult recipients of peripheral blood alloSCTs from MUD.

U2 - 10.1038/s41375-024-02225-7

DO - 10.1038/s41375-024-02225-7

M3 - SCORING: Journal article

C2 - 38538862

VL - 38

SP - 1156

EP - 1163

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 5

ER -